Viewing Study NCT00727090


Ignite Creation Date: 2025-12-18 @ 7:02 AM
Ignite Modification Date: 2025-12-23 @ 9:58 PM
Study NCT ID: NCT00727090
Status: None
Last Update Posted: 2022-03-28 00:00:00
First Post: 2008-07-30 00:00:00
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients
Sponsor: None
Organization:

Study Overview

Official Title: Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients
Status: None
Status Verified Date: 2022-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Enrollment below goal.
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Conivaptan (Vaprisol) is FDA-Approved for the treatment of low serum sodium (hyponatremia), but there are few data in patients with neurologic disease. Very low serum sodium in patients with brain injury can be life-threatening and is associated with cerebral edema (swelling of brain tissue). This can be important in patients with brain hemorrhage, brain tumors, or stroke (cerebral infarction).

This is a pilot study to test the hypothesis that conivaptan (Vaprisol) leads to a greater increase in sodium than usual care. Patients will be randomly assigned to usual care or the lower FDA-approved dose of conivaptan (Vaprisol). We will track the use of other interventions, such as the use of hypertonic saline (concentrated salt solution), diuretics and salt tablets. A blinded co-investigator will record neurologic examination results (NIH Stroke Scale and Glasgow Coma Scale).
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: